hight dose vitamin D (n=130) vs. Vitamin D (n=130)
randomized controlled trial
high risk of bias
high dose vitamin D3 (400,000 IU)
single oral high dose of cholecalciferol (vitamin D3) administered within 72 hours after the diagnosis of COVID-19
standard-dose vitamin D3 (50,000 IU)
COVID-19 mild to moderate
≥65 years, had SARS-CoV-2 infection of less than 3 days, and at least 1 COVID-19 worsening risk factor (among age ≥75 years, SpO2 ≤94%, or PaO2/FiO2 ≤300 mm Hg)
open-label
9 medical centers in France
ambiguous results table for mortality with 3 analysis methods without mention of the preplanned primary analysis. Whatever, the 14-days censured cox result is not robust given the others 14 days and 28 days results (in particular the 14-days death *rate* comparison, probable preplanned primary analysis according to the published protocol)
Rastogi, 2020 NCT04459247
Vitamin D (n=16) vs. placebo (n=24)
randomized controlled trial
risk of bias NA
Cholecalciferol high dose
Daily 60 000 IU of cholecalciferol (5 mL oral nano-liquid droplets) for 7 days with therapeutic target 25(OH)D>50 ng/ml.
Placebo.
Daily 5 ml distilled water for 7 days.
All the participants received standard care for the SARS-CoV-2 infection and pre-existing co-morbidities as per institute protocol.
COVID-19 mild to moderate
Patients requiring invasive ventilation or with significant comorbidities were excluded.